# Evidence Validation Summary

**Date:** February 25, 2026
**Method:** 24 independent research agents validated every claim against peer-reviewed literature, systematic reviews, meta-analyses, and regulatory databases. 35 individual analyses produced with 200+ sources saved.

---

## 1. Executive Summary

The original documents contain a mix of well-supported biochemistry, moderately supported clinical claims, and significantly overstated or outright incorrect assertions. The most consistent pattern is **tier inflation** -- items are systematically classified one tier higher than the evidence supports. Several items are placed in "Tier 1: Strong Evidence" that belong in Tier 2 or 3. Quantitative claims (e.g., "70% collagen increase," "3.7x healing ratio," "30-50% healing time reduction") are frequently stripped of essential context, making small or preliminary findings sound definitive. Safety concerns are systematically under-disclosed. The peptide section conflates animal/in vitro evidence with human clinical evidence more aggressively than the supplement section. The document reads as if optimized to make the reader feel confident rather than accurately informed -- a classic sycophancy pattern.

---

## 2. Tier Reclassification Table

### Supplements

| Item | Original Tier | Validated Tier | Key Issue | Confidence |
|---|---|---|---|---|
| **Vitamin C** | Tier 1 | Tier 1 (mechanism) / Tier 2 (clinical) | RCT evidence inconsistent; vocal fold claim overcorrected (VF scarring is about HA/elastin, not just collagen) | Medium-High |
| **Zinc** | Tier 1 | Tier 2 | Meta-analysis shows modest RR 1.41, fragile significance; zero scar-specific studies | Medium |
| **Collagen Peptides** | Tier 1 | Tier 2 | "3.7x HR" from N=31 burn pilot, 95% CI 1.4-9.5; "direct building blocks" is mechanistically wrong; industry bias in literature | Medium |
| **Arginine + Glutamine** | Tier 1 | Tier 2 (infection prevention) / Insufficient (scarring) | Meta-analyses measure infectious complications, NOT wound healing quality; benefits limited to malnourished patients; ESPEN gives standalone arginine Grade 0 | Medium |
| **S. boulardii** | Tier 1 | Tier 1 (AAD) / Tier 2 (gut barrier) / Insufficient (wound healing) | Strong for AAD prevention; wound healing connection is indirect and unproven for this organism | Medium-High (AAD) / Low (wound healing) |
| **Topical Silicone** | Tier 1 | Tier 2 | Cochrane reviews rate ALL evidence LOW or VERY LOW certainty by GRADE; 2025 RCT found no difference vs petrolatum; guideline recommendations ≠ strong RCT evidence | Medium |
| **Curcumin** | Tier 2 | Tier 2 (anti-inflammatory) / Tier 3 (anti-scarring) | Zero human scar studies; piperine bioavailability enhancement now disputed; 1000x bioavailability gap for in vitro mechanisms | Low-Medium |
| **Vitamin D3 + K2** | Tier 2 | Tier 2 (D3 immune) / Tier 4 (K2 wound healing) | K2 "tissue repair" claim has zero human wound healing evidence; extrapolated from bone biology | Low (K2) / Medium (D3) |
| **NAC** | Tier 2 | Tier 2 (liver/pulmonary) / Tier 3 (scar reduction) | Scar studies used intradermal injection, not oral; single research group; oral bioavailability <10% | Low-Medium |
| **Bromelain** | Tier 2 | Tier 2 (pain, dental surgery) | Pre-surgical use contradicts fibrinolytic mechanism; vocal cord study was observational combo product (EVAN); bleeding risk paradox | Medium |
| **Quercetin** | Tier 2 | Tier 3 | Only ONE unreplicated animal study for VF scarring; pathway attribution wrong (Smad, not AKT/mTOR); dose not derived from animal data; RCT was cesarean section | Low-Medium |
| **Centella Asiatica** | Tier 2 | Tier 2 (topical) / Tier 3 (oral) | Most clinical scar evidence is topical; oral evidence is two non-randomized registry studies; dose not from scar trials; rare hepatotoxicity risk | Medium (topical) / Low (oral) |
| **Copper** | Tier 3 | Tier 3 (as zinc co-supplement) | Should be reframed as zinc-induced copper depletion prevention; no evidence oral copper enhances wound healing beyond sufficiency | Low |
| **Betaine HCl** | Tier 3 | **REMOVE** | N=6 pilot study only; FDA banned from OTC in 1993; contraindicated with NSAIDs/corticosteroids used post-surgery; "suboptimal stomach acid" claim unsupported; physiologically backwards for surgical stress | Very Low |
| **Glucosamine Chondroitin** | Tier 3 | Tier 3 (generous) | Zero wound healing studies; oral delivery achieves <2% of GAG incorporation; VF researchers use injectable hydrogels, not oral supplementation | Very Low |
| **Boron** | Tier 3 | Tier 3 | Best wound healing evidence is for TOPICAL boron (not oral); inflammatory biomarker data from N=8; EFSA classifies as non-essential | Low |
| **Taurine** | Tier 3 | Tier 3 | One perioperative meta-analysis (reduced infection OR 0.59); no human wound healing RCTs | Low-Medium |
| **MSM** | Tier 3 | Tier 3 (generous) | EFSA rejected collagen formation claim; in vitro study showed MSM DELAYED wound healing at higher concentrations; antiplatelet concerns | Very Low |
| **Gentian + Skullcap** | Tier 3 | **REMOVE or WARN** | Zero wound healing evidence; skullcap has documented hepatotoxicity risk; gentian MAO inhibition interacts with perioperative drugs | Very Low |
| **Calcium D-Glucarate** | Tier 3 | **REMOVE or WARN** | Zero wound healing evidence; modulates glucuronidation of post-surgical drugs (morphine, benzodiazepines, antibiotics) -- no interaction studies exist | Very Low |
| **Sulforaphane** | Tier 3 | Tier 3 | Best of the Tier 3 supplements; strong Nrf2 mechanism; Nrf2 is relevant to wound healing; keloid fibroblast in vitro data; but no surgical recovery RCTs | Low-Medium |
| **Iodine** | Tier 3 | **REMOVE or severely downgrade** | "Antiseptic" claim is a topical-to-oral category error; 1000 mcg/day near UL with thyroid toxicity risk; no oral wound healing evidence | Very Low |

### Peptides

| Item | Original Tier | Validated Tier | Key Issue | Confidence |
|---|---|---|---|---|
| **GHK-Cu** | Featured | Moderate (topical) / Low (injectable) | "4000 genes" from cancer cell lines only; "70% collagen increase" misrepresents in vitro LED combo study; "30-50% healing reduction" unsubstantiated; plasma decline numbers from unpublished 1973 thesis | Low-Medium |
| **TB-500** | Featured | Low | TB-500 is a 7-mer, NOT the 43-mer TB4 -- most cited evidence is for the full protein; half-life is 0.5-2 hours, NOT 7-10 days; cancer risk understated (4x tumor size in mice); no human trials of TB-500 specifically | Low |
| **BPC-157** | Featured | Low | 80%+ of literature from single group (Sikiric/Zagreb) with undisclosed conflicts; zero published negative results (statistical impossibility); only 26 total human subjects ever; cancelled clinical trial without explanation; FDA Category 2 | Low |
| **KPV** | Supporting | Low | Zero human clinical trials for any indication; C. albicans claim used synthetic dimer, not native KPV | Very Low |
| **Thymosin Alpha-1** | Supporting | Medium | Best-established peptide; approved in 35 countries; but "improved survival" claim overstated (study measured immune cell counts, not survival endpoint) | Medium |
| **AHK-Cu / Matrikines** | Supporting | Low (AHK-Cu) / Medium (Matrixyl topical) | AHK-Cu has <5 mechanistic papers; Matrixyl has one human RCT for wrinkles (not scars); no scar-specific studies for either | Low |

### Experimental

| Item | Original Tier | Validated Tier | Key Issue | Confidence |
|---|---|---|---|---|
| **Verteporfin** | Most promising | High (preclinical) / N/A (clinical) | Both Science papers verified; mechanism well-validated; but "33% scar reduction" from N=1 with subjective assessment only; no human efficacy data; trial not enrolling | Medium-High (science) / Very Low (clinical availability) |
| **Botox** | Strong clinical | Medium-High | "20 out of 23 studies" figure could not be verified from any published review; directional claim is accurate; mostly Asian population facial wound data | Medium |
| **Topical Losartan** | Moderate clinical | Low-Medium | Correction: animal scar data is topical, not oral as claimed; still early stage | Low |
| **Pirfenidone Gel** | Moderate clinical | Medium | Claims verified; Mexico approval confirmed; single-center N=63 trial | Medium |
| **PRP** | Moderate clinical | Low-Medium | Piezo1-YAP/TAZ mechanism is from a hypothesis paper, not experimental validation | Low-Medium |
| **Red Light Therapy** | Moderate | Low | GRADE umbrella review: zero high-certainty outcomes; 57% low, 26% very low certainty | Low |
| **HBOT** | Promising preclinical | Low (for acute surgical wounds) | Cochrane: inconclusive for acute wounds; evidence only for chronic wounds | Low |

---

## 3. Items That Should Be REMOVED or Heavily Warned About

1. **Betaine HCl** -- FDA banned from OTC in 1993; contraindicated with post-surgical drugs; N=6 evidence only; physiologically backwards rationale for surgical stress
2. **Gentian + Skullcap** -- Documented hepatotoxicity (skullcap); MAO inhibition interactions (gentian); zero wound healing evidence
3. **Calcium D-Glucarate** -- Modulates drug metabolism of morphine/benzos/antibiotics with no interaction studies; zero wound healing evidence
4. **Iodine** (at 500-1000 mcg) -- Topical-to-oral category error for antiseptic claim; thyroid toxicity risk near UL; only 150 mcg/day justified as deficiency prevention

---

## 4. Significant Factual Errors Found

| Location | Error | Correction |
|---|---|---|
| TB-500 | "Synthetic 43-amino acid peptide fragment" | TB-500 is a 7-amino acid heptapeptide (Ac-LKKTETQ); TB4 is the 43-mer. Most evidence cited is for TB4, not TB-500 |
| TB-500 | "Half-life 7-10 days" | Actual half-life is 0.5-2 hours (PK data). The 7-10 day figure is from bodybuilding forums |
| GHK-Cu | "Increases collagen synthesis by up to 70%" | The 70% figure is COL1 mRNA (not protein) from an LED combination study, not GHK-Cu alone |
| GHK-Cu | "Healing time reductions of 30-50%" | No peer-reviewed study documents this figure; appears on commercial websites only |
| GHK-Cu | "Modulates over 4,000 genes" | Study used MCF7 breast cancer and PC3 prostate cancer cell lines, not fibroblasts or wound tissue |
| Collagen Peptides | "Direct building blocks for wound repair" | Mechanism is indirect signaling via Pro-Hyp dipeptides, not structural incorporation |
| Collagen Peptides | "3.7x wound healing hazard ratio" | From N=31 burn patients receiving multi-component 1000kcal supplement (not pure collagen); 95% CI 1.4-9.5 |
| Quercetin | "Anti-fibrotic via TGF-beta/AKT/mTOR pathway" | The vocal fold paper (PMC9827314) identifies TGF-β1/Smad signaling; AKT/mTOR is from a different tracheal stenosis study |
| Curcumin | Piperine "2000% bioavailability increase" | 2025 pharmacokinetic crossover study found NO significant increase in unconjugated plasma curcumin |
| Topical Losartan | "Oral losartan shown to reduce scarring in animal models" | Animal scar data used topical losartan, not oral |
| PRP | "Bidirectionally modulates via Piezo1-YAP/TAZ axis" | This is from a hypothesis paper, not experimental validation |
| Thymosin Alpha-1 | "Improved postoperative survival in gastric cancer" | Study measured immune cell counts, not survival as primary endpoint |
| KPV | "Antimicrobial against C. albicans" | Study used (CKPV)2 synthetic dimer, not native KPV tripeptide |

---

## 5. Items Where Evidence Was Validated

These items had claims that largely held up:

1. **Vitamin C** -- Biochemistry is textbook-level; collagen cofactor role is incontrovertible; scurvy = failed wound healing is true
2. **Verteporfin** -- Both Science papers verified; mechanism validated; clinical trial real; timing constraints accurately described
3. **Thymosin Alpha-1** -- Best-established peptide; regulatory approval in 35 countries confirmed; dosing validated
4. **Pirfenidone Gel** -- Claims verified; Mexico approval confirmed
5. **HBOT** -- Honestly described ("less clear for acute surgical wounds")
6. **S. boulardii** -- Antibiotic survival mechanism is fundamental biology; AAD prevention well-evidenced
7. **Sulforaphane** -- Nrf2 mechanism is well-characterized; best of the Tier 3 supplements

---

## 6. Key Safety Concerns NOT Mentioned in Original

| Item | Missing Safety Concern |
|---|---|
| **Arginine** | Contraindicated in sepsis (increased mortality); may reactivate herpes simplex |
| **Glutamine** | High doses in multi-organ failure increase mortality (REDOX trial, NEJM 2013) |
| **NAC** | Anticoagulant interaction (decreased platelet aggregation); nitroglycerin interaction; GI intolerance 23%; false lab values |
| **Bromelain** | Fibrinolytic mechanism directly contradicts pre-surgical use recommendation |
| **Betaine HCl** | Contraindicated with NSAIDs/corticosteroids; FDA banned from OTC 1993 |
| **Calcium D-Glucarate** | Modulates metabolism of morphine, benzodiazepines, antibiotics |
| **Gentian** | MAO inhibition interacts with perioperative drugs |
| **Skullcap** | Documented hepatotoxicity; adulteration with germander |
| **Iodine** | Wolff-Chaikoff effect / thyrotoxicosis at upper dose range |
| **MSM** | Antiplatelet properties (bleeding concern post-surgery) |
| **Vitamin C** | Kidney stone risk in men at 1000 mg/day (JAMA Internal Medicine) |
| **Centella Asiatica** | Rare hepatotoxicity (4 published cases) |
| **TB-500** | Cancer risk is understated: 4x tumor size, 4x metastatic nodules in mouse melanoma model |
| **Copper** | Oral copper at 1-2mg does NOT create GHK-Cu complex; conflation with peptide biology is a logical error |
| **K2** | Contraindicated with warfarin/anticoagulants (common post-surgery) |

---

## 7. Overall Assessment

**Original document accuracy: ~55-65% by claim count**

- Biochemical mechanisms are generally correct (~85% accuracy)
- Clinical evidence claims are frequently overstated (~40-50% accurate as stated)
- Quantitative claims are the weakest (~25% accurately contextualized)
- Tier assignments are systematically inflated (every Tier 1 item should be Tier 1-2 or Tier 2; most Tier 2 items should be Tier 2-3)
- Safety disclosures are incomplete (15+ significant safety concerns omitted)

**Patterns of bias detected:**
1. **Sycophantic overconfidence** -- Presenting preclinical evidence as if it's clinical evidence; using superlatives ("strongest," "most important") without comparative data
2. **Context stripping** -- Citing specific numbers (3.7x, 70%, 42-61%) without sample sizes, confidence intervals, or study limitations
3. **Tier inflation** -- Every item is classified optimistically; no item was placed lower than the evidence would support
4. **Route conflation** -- Topical evidence applied to oral supplementation (boron, losartan, iodine); TB4 evidence applied to TB-500
5. **Single-source reliance** -- Several items rely on a single study or research group (BPC-157/Sikiric, GHK-Cu/Pickart, collagen peptides' 3.7x study)
6. **Missing negatives** -- No contradictory evidence, failed studies, or critical reviews are cited anywhere in the original documents

**The document is not unreliable** -- it correctly identifies the most promising intervention categories and the general biochemical frameworks. But a reader relying on it for medical decisions would systematically overestimate the strength of evidence and underestimate the risks. The most important correction needed is adding honest uncertainty throughout.